Ressources numériques en sciences humaines et sociales OpenEdition Nos plateformes OpenEdition Books OpenEdition Journals Hypothèses Calenda Bibliothèques OpenEdition Freemium Suivez-nous

Patient and care partner perspectives on safety considerations for approved gene therapy treatments for rare diseases (from Catapult’s regulatory round-up for November 2024)

The FDA Center for Biologics Evaluation and Research (CBER) hosted a public patient listening meeting on the 20th September 2024 and opened a docket to better understand patient and care partner perspectives on safety considerations and long term follow-up for approved gene therapy treatments for rare diseases. The video recording of this meeting is available here.

Published on the 3rd of december 2024. Read the entire Regulatory Round-up – November 2024 here.


OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (12 février 2025). Patient and care partner perspectives on safety considerations for approved gene therapy treatments for rare diseases (from Catapult’s regulatory round-up for November 2024). ELSIBI. Consulté le 18 mars 2025 à l’adresse https://doi.org/10.58079/13axm


Vous aimerez aussi...

Laisser un commentaire

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *

This site uses Akismet to reduce spam. Learn how your comment data is processed.